Halozyme TherapeuticsHALO +3.17%92 PEG Ratio is 0.60 as of Jul. 02, 2026, which is 18% above its 10-year median of 0.51. GuruFocus rates HALO with a GF Score™ of 92/100 and a GF Value™ of $90.65 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 95 Biotechnology companies, Halozyme Therapeutics ranks better than 77.89% on this metric.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Halozyme Therapeutics's PEG Ratio or its related term are showing as below:
HALO'
s PEG Ratio Range Over the Past 10 Years
Min: 0.25 Med: 0.51 Max: 0.62
Current: 0.6
During the past 13 years, Halozyme Therapeutics's highest PEG Ratio was 0.62. The lowest was 0.25. And the median was 0.51.
HALO's PEG Ratio is ranked better than 77.89% of 95
companies
in the Biotechnology industry
Industry Median: 2.02
vs HALO: 0.60
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Halozyme Therapeutics (NAS:HALO) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Halozyme Therapeutics's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Halozyme Therapeutics PEG Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Halozyme Therapeutics's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Halozyme Therapeutics's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Halozyme Therapeutics (HALO) has a PEG Ratio of 0.60 as of Jul. 02, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Halozyme Therapeutics and its competitors. This is 18% above median its historical median of 0.51. Over the past decade, Halozyme Therapeutics' PEG Ratio has ranged from 0.25 to 0.62. According to the industry distribution chart, Halozyme Therapeutics ranks #21 out of 95 companies in the Biotechnology industry, placing it in the top 22.1%.
Is Halozyme Therapeutics' PEG Ratio too high?
Halozyme Therapeutics' current PEG Ratio of 0.60 is 18% above median its 10-year median of 0.51. Over the past 10 years, this metric has ranged from a low of 0.25 to a high of 0.62. The Biotechnology industry median PEG Ratio is 2.02. Halozyme Therapeutics' value of 0.60 is 70.3% below this industry median. Based on the distribution chart, Halozyme Therapeutics ranks #21 out of 95 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Halozyme Therapeutics has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Halozyme Therapeutics' PEG Ratio compare to KYMR and IBRX?
According to the Biotechnology industry distribution chart, Halozyme Therapeutics ranks #21 out of 95 companies for PEG Ratio. This places Halozyme Therapeutics in the top 22% of its industry — outperforming the majority of peers. The industry median PEG Ratio is 2.02. Halozyme Therapeutics' value of 0.60 is 70.3% below this benchmark. Historically, Halozyme Therapeutics' own PEG Ratio has ranged from 0.25 to 0.62 over the past decade. While the company's 10-year median is 0.51 vs. the industry median of 2.02, Halozyme Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Biotechnology company?
The median PEG Ratio among Biotechnology companies is 2.02, based on 95 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Halozyme Therapeutics's current PEG Ratio of 0.60 is 70.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Halozyme Therapeutics and its competitors. For the Biotechnology industry, the median PEG Ratio is 2.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Halozyme Therapeutics's current PEG Ratio is 0.60, which is 18% above median its own 10-year median of 0.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Halozyme Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Halozyme Therapeutics (HALO) is currently considered Modestly Undervalued. The stock's GF Value™ is $90.65, compared to a current price of $79.47 — trading 12.3% below its estimated fair value. The current PEG Ratio is 0.60, which is 18% above median its 10-year median of 0.51 and 70.3% below the Biotechnology industry median of 2.02. Halozyme Therapeutics' overall GF Score™ is 92/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Halozyme Therapeutics (HALO), the current PEG Ratio is 0.60 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Halozyme Therapeutics (HALO) Overvalued in 2026?
Based on GuruFocus' analysis, Halozyme Therapeutics stock appears to be undervalued.
The current stock price of $79.47 is trading 12.3% below its estimated GF Value™ of $90.65.
GuruFocus considers Halozyme Therapeutics to be Modestly Undervalued.
Key valuation signals for HALO:
PEG Ratio: 0.60 (18% above median its 10-year median of 0.51)
GF Value™: $90.65 vs. price of $79.47 (12.3% below fair value)
Industry Position: 70.3% below the Biotechnology median (#21 of 95)
No single metric tells the full story. See the HALO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.
92GF Score
Get the complete analysis for HALO
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HALO has been successfully added to your 
